Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06724549Phase 1Completed

The Effect of Food on the Pharmacokinetics of BN104 Tablets

Role: lead

NCT06746519Phase 1Recruiting

BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

Role: collaborator

NCT05611853Phase 1Terminated

Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Role: lead

NCT04930562Phase 2Completed

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

Role: lead

NCT05365100Phase 1Withdrawn

A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

Role: lead

All 5 trials loaded